ESPMEDIUM SIGNALFINANCIAL10-K

ESP reported strong financial performance with substantially higher operating cash flow and notable growth across key profitability metrics, driven by increased power supply contract shipments.

The company demonstrates solid operational execution with net income growing 40% and operating cash flow roughly doubling year-over-year, indicating strong cash conversion from earnings. The substantial increase in export shipments and expanded customer concentration suggests ESP is successfully scaling its power supply business internationally.

Comparing 2025-09-16 vs 2024-09-27View on EDGAR →
FINANCIAL ANALYSIS

ESP's financial position strengthened meaningfully with current assets expanding 41% and stockholders' equity growing 23%, though current liabilities also increased substantially by 85%. The company achieved broad-based growth with gross profit up 19%, operating income advancing 24%, and net income climbing 40%, while operating cash flow roughly doubled to $21 million. The overall picture signals a company in a strong growth phase with improving profitability and cash generation, though the sharp rise in liabilities warrants monitoring.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+98.1%
$10.6M$21.0M

Operating cash flow surged 98.1% — exceptional cash generation, highest quality earnings signal.

Total Liabilities
Balance Sheet
+85.1%
$15.3M$28.3M

Liabilities grew 85.1% — significant increase in debt or obligations, assess impact on financial flexibility.

Current Liabilities
Balance Sheet
+85.1%
$15.3M$28.3M

Current liabilities surged 85.1% — significant near-term obligations; verify ability to meet short-term debt.

Current Assets
Balance Sheet
+41.2%
$53.2M$75.2M

Current assets grew 41.2% — improving short-term liquidity or inventory/receivables build.

Net Income
P&L
+40%
$5.8M$8.1M

Net income grew 40% — bottom-line growth signals improving overall business health.

Total Assets
Balance Sheet
+39.9%
$56.5M$79.1M

Asset base grew 39.9% — expansion through organic growth, acquisitions, or capital deployment.

Operating Income
P&L
+24.3%
$6.5M$8.1M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Stockholders Equity
Balance Sheet
+23.2%
$41.3M$50.8M

Equity base grew 23.2% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Gross Profit
P&L
+19.1%
$10.7M$12.7M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Accounts Receivable
Balance Sheet
+14.5%
$6.6M$7.6M

Receivables grew 14.5% — monitor days sales outstanding for collection efficiency.

LANGUAGE CHANGES
NEW — 2025-09-16
PRIOR — 2024-09-27
ADDED
ESP 20250630 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
At September 14, 2025 there were 2,924,418 shares outstanding of the registrant's Common stock, $.33-1/3 par value.
In fiscal years ended June 30, 2025 and 2024, the Company's total sales were $43,950,872 and $38,736,319, respectively.
Sales to six customers accounted for 16%, 13%, 12%, 12%, 11% and 10%, respectively, of total sales in 2025.
Export shipments in fiscal years 2025 and 2024 were $3,124,820 and $2,350,087, respectively.
+7 more — sign up free →
REMOVED
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
At September 24, 2024 there were 2,744,458 shares outstanding of the registrant's Common stock, $.33-1/3 par value.
In fiscal years ended June 30, 2024 and 2023, the Company's total sales were $38,736,319 and $35,592,323, respectively.
Sales to five domestic customers accounted for 23%, 18%, 16%, 13% and 11%, respectively, of total sales in 2023.
Export shipments in fiscal years 2024 and 2023 were $2,350,087 and $549,510, respectively.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →